[
Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity
[og_img]
https://www.investing.com/news/press-releases/sensorion-announces-the-end-of-patient-inclusion-in-notoxis-phase-2a-clinical-trial-of-sens401-for-the-prevention-of-cisplatininduced-ototoxicity-93CH-3914111
Investing.com
Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity
Related articles
